MVdeltaC
Pleural Mesothelioma
Pre-clinicalActive; FDA Orphan Drug Designation granted
Key Facts
Indication
Pleural Mesothelioma
Phase
Pre-clinical
Status
Active; FDA Orphan Drug Designation granted
Company
About Oncovita
Oncovita is a spin-off from Institut Pasteur dedicated to developing life-saving cancer treatments using its proprietary Measovir® platform, a modified measles virus vector. The company has secured exclusive worldwide licensing rights from Institut Pasteur and is advancing its lead candidate, MVdeltaC, for pleural mesothelioma, which has received FDA Orphan Drug Designation. Led by a seasoned management team, Oncovita is building a pipeline of oncolytic virus candidates and has established strategic partnerships with entities like Infinitusbio.AI and Unither Pharmaceuticals to accelerate development.
View full company profile